Bilaketaren emaitzak - Jan Müller‐Brand

  • Erakusten 1 - 14 emaitzak -- 14
Findu emaitzak
  1. 1
    Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium

    Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium nork A Blumberg, H.W. Roser, C Zehnder, Jan Müller‐Brand

    Argitaratua 1997
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease

    The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease nork Martin A. Walter, R Melzer, Christian Schindler, Jan Müller‐Brand, Alan Tyndall, Egbert Nitzsche

    Argitaratua 2005
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study

    The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study nork Martin A. Walter, Christian P. Turtschi, Christian Schindler, Peter Minnig, Jan Müller‐Brand, Beat P. Müller‐Stich

    Argitaratua 2007
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study

    In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study nork Flavio Forrer, Jianhua Chen, Melpomeni Fani, P. Powell, Andreas Lohri, Jan Müller‐Brand, Gerhard Moldenhauer, Helmut R. Maëcke

    Argitaratua 2009
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Somatostatin Receptor–Targeted Radiopeptide Therapy with <sup>90</sup>Y-DOTATOC and <sup>177</sup>Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial

    Somatostatin Receptor–Targeted Radiopeptide Therapy with <sup>90</sup>Y-DOTATOC and <sup>177</sup>Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Tri... nork Nicolas Marincek, Piotr Radojewski, Rebecca A. Dumont, Philippe Brunner, Jan Müller‐Brand, Helmut R. Maëcke, Matthias Briel, Martin A. Walter

    Argitaratua 2015
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial

    Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial nork Dominik Cordier, Flavio Forrer, Frank Bruchertseifer, Alfred Morgenstern, Christos Apostolidis, Stephan Good, Jan Müller‐Brand, Helmut R. Mäcke, J.C. Reubi, Adrian Merlo

    Argitaratua 2010
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials

    Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials nork Martin A. Walter, Matthias Briel, Mirjam Christ‐Crain, Steen Joop Bonnema, John Connell, David S. Cooper, Heiner C. Bucher, Jan Müller‐Brand, Beat P. Müller‐Stich

    Argitaratua 2007
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

    Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours nork Anna Romer, Daniela Seiler, Nicolas Marincek, Philippe Brunner, Michael Koller, Quinn K.T. Ng, Helmut R. Maëcke, Jan Müller‐Brand, Christoph Rochlitz, Matthias Briel, Christian Schindler, Martin A. Walter

    Argitaratua 2013
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Cohort Study of Somatostatin-Based Radiopeptide Therapy With [<sup>90</sup>Y-DOTA]-TOC Versus [<sup>90</sup>Y-DOTA]-TOC Plus [<sup>177</sup>Lu-DOTA]-TOC in Neuroendocrine Cancers

    Cohort Study of Somatostatin-Based Radiopeptide Therapy With [<sup>90</sup>Y-DOTA]-TOC Versus [<sup>90</sup>Y-DOTA]-TOC Plus [<sup>177</sup>Lu-DOTA]-TOC in Neuroendocrine Cancers nork Linda Villard, Anna Romer, Nicolas Marincek, Philippe Brunner, Michael Koller, Christian Schindler, Quinn K.T. Ng, Helmut R. Mäcke, Jan Müller‐Brand, Christoph Rochlitz, Matthias Briel, Martin A. Walter

    Argitaratua 2012
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk

    Progression to Overt or Silent CAD in Asymptomatic Patients With Diabetes Mellitus at High Coronary Risk nork Michael J. Zellweger, Michael Maraun, Hans H. Osterhues, Ulrich Keller, Jan Müller‐Brand, Raban Jeger, Otmar Pfister, Thilo Burkard, Friedrich Eckstein, Stefanie von Felten, Stefan Osswald, Matthias Pfisterer

    Argitaratua 2014
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer

    Procalcitonin levels predict clinical course and progression‐free survival in patients with medullary thyroid cancer nork Martin A. Walter, Christian Meier, Tanja Radimerski, Fabienne Iten, Marius Kränzlin, Jan Müller‐Brand, Jan Willem B. de Groot, Ido P. Kema, Thera P. Links, Beat P. Müller‐Stich

    Argitaratua 2009
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors

    Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors nork Nancy Sharma, Boris G. Naraev, Eric G. Engelman, M. Bridget Zimmerman, David Bushnell, Thomas M. O’Dorisio, M. Sue O’Dorisio, Yusuf Menda, Jan Müller‐Brand, James R. Howe, Þorvarður R. Hálfdánarson

    Argitaratua 2016
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors

    The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors nork Philippe Brunner, Ann-Catherine Jörg, Katharina Glatz, Lukas Bubendorf, Piotr Radojewski, M Umlauft, Nicolas Marincek, Petar-Marko Spanjol, Thomas Krause, Rebecca A. Dumont, Helmut R. Maëcke, Jan Müller‐Brand, Matthias Briel, Anja Schmitt, Aurel Perren, Martin A. Walter

    Argitaratua 2016
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis

    The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis nork Martin Fuchs, Matthias Briel, Thomas Daikeler, Ulrich A. Walker, Helmut Rasch, Scott Berg, Quinn K.T. Ng, Heike Raatz, David Jayne, Ina Kötter, Daniël Blockmans, María C. Cid, Sergio Prieto‐González, Peter Lamprecht, Carlo Salvarani, Zaharenia Th. Karageorgaki, Richard A. Watts, Raashid Luqmani, Jan Müller‐Brand, Alan Tyndall, Martin A. Walter

    Argitaratua 2011
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: